Clinical Trials Logo

Active Psoriatic Arthritis clinical trials

View clinical trials related to Active Psoriatic Arthritis.

Filter by:
  • None
  • Page 1

NCT ID: NCT04314544 Recruiting - Clinical trials for Active Psoriatic Arthritis

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Start date: July 1, 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

NCT ID: NCT04314531 Recruiting - Clinical trials for Active Psoriatic Arthritis

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Start date: July 1, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .

NCT ID: NCT03881059 Active, not recruiting - Clinical trials for Active Psoriatic Arthritis

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Start date: March 28, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.

NCT ID: NCT03357471 Completed - Clinical trials for Active Psoriatic Arthritis

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Start date: November 3, 2017
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and effectively self-inject Certolizumab Pegol (CZP) using the e-Device and to evaluate the post-use structural integrity of used devices and cassettes via visual examination.

NCT ID: NCT02980692 Completed - Clinical trials for Active Psoriatic Arthritis

Efficacy and Safety Study of SUNPG1623

Start date: May 17, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623